TONMYA Administration in Children: Not Approved for Pediatric Use
TONMYA (sublingual cyclobenzaprine) is not approved for use in children and should not be administered to pediatric patients. The FDA-approved indication is exclusively for treatment of fibromyalgia in adults 1.
Why TONMYA Cannot Be Used in Children
Lack of Pediatric Approval
The prescribing information for TONMYA explicitly limits its use to adults only 1. There are no established pediatric dosing guidelines, safety data, or efficacy studies in children for this sublingual formulation.
Specific Adult-Only Considerations
The drug label provides dosing modifications only for:
- Adults: Standard dose of 5.6 mg (2 sublingual tablets) at bedtime
- Geriatric patients: Reduced dose of 2.8 mg (1 tablet) at bedtime
- Hepatic impairment: Reduced dose of 2.8 mg for mild impairment 1
No pediatric dosing exists because the medication has not been studied or approved for this population.
Important Safety Concerns
Embryofetal Toxicity Risk
TONMYA carries warnings about neural tube defects based on animal studies, requiring pregnancy testing before initiation in females of reproductive potential 1. This underscores the medication's potential for serious developmental effects, making pediatric use particularly concerning without appropriate safety data.
Sublingual Administration Complexity
The administration requirements are designed for adults:
- Must be placed under the tongue until dissolved
- Cannot be swallowed whole, cut, crushed, or chewed
- Requires avoiding eating/drinking for 15 minutes after administration
- Requires avoiding talking for 5 minutes after administration 1
These requirements would be extremely difficult to ensure compliance with in pediatric patients, particularly younger children.
Alternative Considerations
If a child requires treatment for a condition where cyclobenzaprine might be considered (such as muscle spasm, not fibromyalgia), traditional oral cyclobenzaprine formulations would need to be evaluated by the prescribing physician. However, even standard cyclobenzaprine has limited pediatric data and is generally not recommended for children under 15 years of age.
The bottom line: Do not attempt to administer TONMYA to children. This medication is adult-only, and attempting pediatric use would be off-label without any supporting safety or efficacy data.